4 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq) - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Macquarie University, Australia | 12 | 2024-11-15 | 2025-06-08 |
| Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 202 | 2022-01-11 | 2026-10-21 |
| Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 384 | 2020-11-13 | 2026-07-20 |
| An Efficacy and Safety Study of Ravulizumab in ALS Participants Placebo, Ravulizumab - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 382 | 2020-03-30 | 2023-01-10 |
Amyotrophic Lateral Sclerosis (2) · Motor Neuron Disease (1)
Central Nervous System Diseases (2) · Metabolic Diseases (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Nutritional and Metabolic Diseases (2) · Proteostasis Deficiencies (2) · Spinal Cord Diseases (2) · TDP-43 Proteinopathies (2) · Motor Neuron Disease (1)
Edaravone (2) · Lamivudine (1) · abacavir (1) · abacavir, dolutegravir, and lamivudine drug combination (1) · dolutegravir (1) · ravulizumab (1)
Shionogi (2) · Alexion Pharmaceuticals, Inc. (1) · Macquarie University, Australia (1)
Canada (3) · Germany (3) · Japan (3) · Switzerland (3) · United States (3) · Australia (2) · Italy (2) · South Korea (2) · Belgium (1) · Denmark (1) · France (1) · Ireland (1) · Israel (1) · Netherlands (1) · Poland (1)
2019 (2)